Skip to content

Evaluation the effect of terazosin in reducing vascular stiffness: a prospective, multicenter, observational clinical study

Evaluation the effect of terazosin in reducing vascular stiffness: a prospective, multicenter, observational clinical study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040605
Enrollment
Unknown
Registered
2020-12-03
Start date
2020-12-15
Completion date
Unknown
Last updated
2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular stiffness

Interventions

2mg terazosin with hypertension:2mg terazosin
1mg terazosin with hypertension:1mg terazosin
0.5mg terazosin with hypertension:0.5mg terazosin
0.2mg tamsulosin with hypertension:0.2mg tamsulosin
hypertension patients without the need of alpha - adrenergic receptor blockers:hypertension control
2mg terazosin without hypertension :2mg terazosin
1mg terazosin without hypertension:1mg terazosin
0.5mg terazosin without hypertension:0.5mg terazosin
0.2mg tamsulosin without hypertension:0.2mg tamsulosin
individuals without hypertension and the need of alpha - adrenergic receptor blockers:Normal blood pressure control

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male aged between 40 and 70 years; 2. PWV increased abnormally, exceeding the normal reference value (1400m/s) or considered as stiffness; 3. Without hard cardiovascular disease, including coronary heart disease,acute myocardial infarction, large artery hemangioma and stroke; 4. Normal hepatic and renal functions; 5. Without hematological disorders; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have taken terazosin or tamsulosin or other a - adrenergic receptor blockers in the past three months; 2. Need to take type 5 phosphodiesterase inhibitors for erectile dysfunction or other diseases; 3. Need to take hypoglycemic drugs or lipid lowering drugs due to abnormal blood glucose or blood lipid; 4. Individuals with angina pectoris, myocardial disease, valvular disease and coronary artery disease; 5. Patients with malignant tumor; 6. Unable to cooperate with treatment and follow-up; 7. Taking drugs that affect coagulation function and platelet function; 8. Participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
related gene sequencing results;related gene sequencing results;

Countries

China

Contacts

Public ContactCuntai Zhang

Department of geriatrics, Tongji Hospital

ctzhang0425@163.com+86 15927668408

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026